Abstract
A new subtype of myositis syndrome, immune-mediated necrotizing myopathy (IMNM), was initially explained in 2004. It manifests as symmetrical proximal muscular weakness in the extremities fairly quickly, with no obvious inflammatory infiltrate and significant muscle fiber necrosis and regeneration. According to the specific autoantibodies in patients, Anti-HMGCR+, anti-SRP+, and antibody-negative IMNM are the three subtypes of IMNM. which are characterized by subtle differences in pathogenesis, clinical manifestations, and therapeutic approaches. The aim of this review is to sort out most of the current studies on IMNM, to provide detailed explanations of their pathogenesis, diagnostic techniques and therapeutic approaches, and to summarize some of the protein molecules and structures that may play a key role in myopathogenesis. We hope that this will help to deepen the understanding of IMNM pathogenesis and optimize therapeutic strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
